Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Accelerated Approval after Bracelet-1

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 05, 2022 2:16pm

180 Views

Post# 35151566

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Accelerated Approval after Bracelet-1

ONCY is working its way towards the approval of pelareorep in the treatment of HR+ (positive) / HER2- (negative) metastatic breast cancer while Enhertu is approved for HR+/- (positive/negative) / HER2 (low) metastatic breast cancer - a significant difference between the two types of mBC.

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Nov. 22, 2024)